Targeted in vivo Generation of CAR T and NK Cells Utilizing an Engineered Lentiviral Vector Platform
June 22, 2023
Download the poster here.
News + Press
Explore by Category
Targeted in vivo Generation of CAR T and NK Cells Utilizing an Engineered Lentiviral Vector Platform
June 22, 2023
Download the poster here.
Interius BioTherapeutics Highlights Strong Preclinical Data Supporting In Vivo Chimeric Antigen Receptor (CAR) Vector Evaluation in Clinic
June 21, 2023
PHILADELPHIA, June 21, 2023 /PRNewswire/ — Interius BioTherapeutics, a leading developer of in vivo cell-specific genetic medicine therapeutics, today announced…
Interius BioTherapeutics Announces Successful Manufacturing Partnership with WuXi Advanced Therapies
May 09, 2023
PHILADELPHIA, May 9, 2023 /PRNewswire/ — Interius BioTherapeutics, a preclinical stage gene therapy company developing novel methods for…
Interius BioTherapeutics Hosts Immersive, Hands-on Event to Ignite Students’ Passion for Science
April 27, 2023
Philadelphia, PA – April 27, 2023 – Interius BioTherapeutics, a preclinical stage gene therapy company…
Nature Magazine Coverage: Ensoma and Interius BioTherapeutics: in vivo veritas
August 26, 2022
An innovation showcase of protein degraders, RNA therapeutics, delivery vectors and gene modifiers
Interius Bio Announces Granting of US Patent to Support in Vivo Cell-Specific Gene Delivery Platform
December 09, 2021
Company also celebrates “Deal of the Year” awarded by The Penn Center for Innovation PHILADELPHIA,…
Pennovation Lab Welcomes New Tenant Interius BioTherapeutics to Its Innovation Ecosystem
October 05, 2021
Interius BioTherapeutics Raises $76M Series A Financing to Advance Breakthrough Cell and Gene Therapy Platform
May 18, 2021
Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, today announced that it has raised $76 million in an oversubscribed Series A financing.